Literature DB >> 2503543

Endotoxin induction of tumor necrosis factor is enhanced by acid-labile interferon-alpha in acquired immunodeficiency syndrome.

A S Lau1, J F Livesey.   

Abstract

High levels of an acid-labile IFN-alpha have been demonstrated in the sera of patients with symptomatic HIV infection. IFNs have been shown to enhance the cytotoxic and antiproliferative actions of tumor necrosis factor (TNF), which is a potent mediator of inflammation and sepsis. We show that the acid-labile IFN-alpha present in AIDS sera can induce TNF synthesis and sensitize blood monocytes (BM) to endotoxin stimulation resulting in further synthesis of TNF in vitro. TNF production by BM from patients with HIV infections and normal controls was measured by a cytotoxicity assay on L929 cells using human TNF alpha as a standard. BM from AIDS patients spontaneously produce high levels of TNF and are hypersensitive to endotoxin stimulation, resulting in enhanced synthesis of TNF. In determining the mechanism involved, we demonstrated that treatment of normal BM with AIDS sera results in induction of TNF. Neutralization of the acid-labile IFN-alpha in AIDS sera with polyclonal anti-IFN-alpha antibodies results in diminution of TNF induction. In addition, pretreatment of normal BM with AIDS sera, IFN-alpha, or IFN-gamma renders the cells hypersensitive to endotoxin. Consequently, activation of the TNF system by the acid-labile IFN-alpha contributes to some of the physiological disturbances, such as the wasting syndrome, and to the pathophysiology of sepsis in AIDS patients.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2503543      PMCID: PMC329714          DOI: 10.1172/JCI114231

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  29 in total

Review 1.  The role of cachectin/TNF in endotoxic shock and cachexia.

Authors:  A Cerami; B Beutler
Journal:  Immunol Today       Date:  1988-01

Review 2.  Acquired immune deficiency syndrome in childhood.

Authors:  K M Shannon; A J Ammann
Journal:  J Pediatr       Date:  1985-02       Impact factor: 4.406

3.  Characterization of receptors for human tumour necrosis factor and their regulation by gamma-interferon.

Authors:  B B Aggarwal; T E Eessalu; P E Hass
Journal:  Nature       Date:  1985 Dec 19-1986 Jan 1       Impact factor: 49.962

4.  Induction of the synthesis of tumor necrosis factor receptors by interferon-gamma.

Authors:  V Ruggiero; J Tavernier; W Fiers; C Baglioni
Journal:  J Immunol       Date:  1986-04-01       Impact factor: 5.422

5.  Elevated levels of interferon-induced 2'-5' oligoadenylate synthetase in generalized persistent lymphadenopathy and the acquired immunodeficiency syndrome.

Authors:  S E Read; B R Williams; R A Coates; W K Evans; M M Fanning; M B Garvey; F A Shepherd
Journal:  J Infect Dis       Date:  1985-09       Impact factor: 5.226

6.  Regulation of interleukin 1 production by alpha and beta interferons: evidence for both direct and indirect enhancement.

Authors:  R V Candler; B T Rouse; R N Moore
Journal:  J Interferon Res       Date:  1985

7.  Participation of tumor necrosis factor in the mediation of gram negative bacterial lipopolysaccharide-induced injury in rabbits.

Authors:  J C Mathison; E Wolfson; R J Ulevitch
Journal:  J Clin Invest       Date:  1988-06       Impact factor: 14.808

8.  Synergism between gamma interferon and lipopolysaccharide for synthesis of factor B, but not C2, in human fibroblasts.

Authors:  Y Katz; F S Cole; R C Strunk
Journal:  J Exp Med       Date:  1988-01-01       Impact factor: 14.307

9.  Lack of binding of bacterial lipopolysaccharide to mouse lung macrophages and restoration of binding by gamma interferon.

Authors:  K S Akagawa; T Tokunaga
Journal:  J Exp Med       Date:  1985-11-01       Impact factor: 14.307

10.  Modulation of endothelial cell hemostatic properties by tumor necrosis factor.

Authors:  P P Nawroth; D M Stern
Journal:  J Exp Med       Date:  1986-03-01       Impact factor: 14.307

View more
  9 in total

1.  Spontaneous release of interferon as a predictor of clinical evolution in HIV-positive subjects.

Authors:  A Biglino; A Surbone; F Lipani; N Cappello; B Forno; A M Pollono; M Busso; A Pugliese
Journal:  Infection       Date:  1991 Jan-Feb       Impact factor: 3.553

2.  A platelet-activating factor antagonist, RP 55778, inhibits cytokine-dependent induction of human immunodeficiency virus expression in chronically infected promonocytic cells.

Authors:  D Weissman; G Poli; A Bousseau; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-15       Impact factor: 11.205

3.  Systemic tumor necrosis factor-alpha production in experimental colitis.

Authors:  D R Mack; A S Lau; P M Sherman
Journal:  Dig Dis Sci       Date:  1992-11       Impact factor: 3.199

4.  Tumor necrosis factor and interferon as prognostic markers in human immunodeficiency virus (HIV) infection.

Authors:  G Hess; S Rossol; R Rossol; K H Meyer zum Büschenfelde
Journal:  Infection       Date:  1991       Impact factor: 3.553

5.  Elevated serum levels of soluble tumour necrosis factor receptors (sTNF-R) in patients with HIV infection.

Authors:  A Kalinkovich; H Engelmann; N Harpaz; R Burstein; V Barak; I Kalickman; D Wallach; Z Bentwich
Journal:  Clin Exp Immunol       Date:  1992-09       Impact factor: 4.330

6.  Apoptosis induced by tumor necrosis factor in cells chronically infected with feline immunodeficiency virus.

Authors:  K Ohno; T Nakano; Y Matsumoto; T Watari; R Goitsuka; H Nakayama; H Tsujimoto; A Hasegawa
Journal:  J Virol       Date:  1993-05       Impact factor: 5.103

7.  Pentoxifylline prevents indomethacin induced acute gastric mucosal damage in rats: role of tumour necrosis factor alpha.

Authors:  L Santucci; S Fiorucci; M Giansanti; P M Brunori; F M Di Matteo; A Morelli
Journal:  Gut       Date:  1994-07       Impact factor: 23.059

8.  Sleep electroencephalogram delta-frequency amplitude, night plasma levels of tumor necrosis factor alpha, and human immunodeficiency virus infection.

Authors:  D F Darko; J C Miller; C Gallen; J White; J Koziol; S J Brown; R Hayduk; J H Atkinson; J Assmus; D T Munnell; P Naitoh; J A McCutchan; M M Mitler
Journal:  Proc Natl Acad Sci U S A       Date:  1995-12-19       Impact factor: 11.205

9.  Effect of a recombinant HIV gp160 vaccine on monokine production.

Authors:  D P Dooley; R A Cox; D J Looney
Journal:  Clin Exp Immunol       Date:  1991-02       Impact factor: 4.330

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.